Iressa Survival Study Is Ahead Of Schedule, AstraZeneca Says

AstraZeneca plans to meet with FDA and clinical investigators to discuss the progress of a lung cancer survival study of Iressa (gefitinib) once it sees the "details" of a study showing improved survival in patients treated with Genentech/OSI's Tarceva (erlotinib)